Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4
Dianhua Jiang(Cedars-Sinai Medical Center), Paul W. Noble(Cedars-Sinai Medical Center), Jiurong Liang(Cedars-Sinai Medical Center), Yuejuan Li(Duke University), Andrew D. Luster(Harvard University), Rishu Guo(University of North Carolina at Chapel Hill), Robert Homer(Yale University), Gabriele Campanella(Icahn School of Medicine at Mount Sinai), Eric B. Meltzer(Duke University), Ting Xie(Cedars-Sinai Medical Center), Paul F. Goetinck(Harvard University), Shuang Yu(Heilongjiang University of Chinese Medicine), Ningshan Liu(Duke University), Yoosun Jung(Duke University), Andrew M. Tager(Harvard University)
Cited by 165
Related Papers
Clinical-grade computational pathology using weakly supervised deep learning on whole slide images
|Nature Medicine|2019|2.6k
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
|The Lancet|2011|2.1k
Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity
|Annual Review of Immunology|2014|2.1k
Toll-like receptors stimulate human neutrophil function
|Blood|2003|927